^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UF-KURE19

    i
    Other names: UF-KURE19, UF-KURE19 CAR-T
    Associations

    News

    Trials
    Company:
    Case Comprehensive Cancer Center, Kure.ai
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day (ASH 2023)
    The product passed all release criteria for infusion and was administered to the patient after lymphodepletion with fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 daily for 3 days. UF-Kure19 cells expanded robustly in the patient and peaked around day 10 (23% of circulating CD3) with a strong skewing of CD4/CD8 cells (93% CD8+ T cells on day 10)...In vitro and animal data suggest this fast-manufacturing platform leads to potent CAR-T cells. Early human testing indicates CAR-T cells generated using this novel system have clinical activity against hematologic malignancies.
    Clinical • CAR T-Cell Therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • UF-KURE19
    over1year
    Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=10, Recruiting, James Michael Martin | Trial completion date: Dec 2026 --> Dec 2024 | Initiation date: Oct 2023 --> Apr 2023 | Trial primary completion date: Jun 2026 --> Jun 2024
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • UF-KURE19
    2years
    Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=10, Recruiting, James Michael Martin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • UF-KURE19
    over2years
    Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, James Michael Martin
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • UF-KURE19